Syndax Pharmaceuticals, Inc.

US$9.54As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SNDXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (2.11%)
Div yield —
ROE (426.43%)
Biotechnology
Beta (5Y) 0.45
PE TTM —
TSR TTM (30.36%)
Mkt cap US$858.9M
ROIC (21.61%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
19.05%
(32.37%)
Hold 12|0|6|5|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.21
0.22
0.24
0.26
38.20%
31.17%
29.92%
24.54%
Revenue$M
62.21
65.58
64.99
67.85
8.85%
17.60%
12.51%
12.86%
Peers (US$858.9M)
Cap (US$)
PE
864.4M
9.592x
866.6M
—
Capital
TTM
5Y
10Y
Leveragex
1.098
0.037
0.037
EBIT/Intx
4.513
0.308
0.324
Own earn%
71.73
135.06
133.73
Sh yield%
38.89
22.39
24.81
Owners
Insiders/Inst%
13.09
69.92
Short interest%
4.67
SBC / revenue%
2.00
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
25–32
$1 testx
—
Incr. ROIC%
10